
SCLX Stock Forecast & Price Target
SCLX Analyst Ratings
Bulls say
Scilex Holding's strategic partnerships are anticipated to provide a predictable and diversified revenue stream, which is likely to enhance its financial stability and enable further research and development initiatives. The innovative products such as SP-102 demonstrate a strong efficacy profile and safety measures, setting them apart from existing therapies, thus potentially capturing a significant market share in the non-opioid pain management sector. Additionally, the impending approval for ELYXYB® in Canada is expected to expand the company's market potential, further solidifying Scilex's position in the pain management landscape.
Bears say
Scilex Holding Co faces a negative outlook primarily due to the cautious market perception, resulting in a lower valuation that reflects broader investor sentiment sensitive to economic factors such as interest rate hikes and regulatory challenges. The company's financials are further strained by its association with Sorrento Therapeutics, which has encountered liquidity issues and market volatility, potentially undermining Scilex's efforts to establish itself independently. Additionally, the application of a 30% discount rate in valuation models emphasizes concerns regarding Scilex's clinical pipeline and product commercialization prospects, compounding the bearish sentiment surrounding the stock.
This aggregate rating is based on analysts' research of Scilex Holding Co and is not a guaranteed prediction by Public.com or investment advice.
SCLX Analyst Forecast & Price Prediction
Start investing in SCLX
Order type
Buy in
Order amount
Est. shares
0 shares